百奧泰(688177.SH):與SteinCares就兩款在研生物類似藥籤署授權許可與商業化協議
格隆匯3月18日丨百奧泰(688177.SH)公佈,公司與SteinCares(簡稱“Stein”)簽署授權許可與商業化協議,將公司的BAT2506(戈利木單抗)注射液和BAT2606(美泊利珠單抗)注射液在巴西以及其餘拉丁美洲地區市場的獨佔的產品商業化權益有償許可給Stein。首付款及里程碑款總金額最高至600萬美元,其中包括120萬美元首付款、累計不超過480萬美元里程碑付款,以及淨銷售額的兩位數百分比作為收入分成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.